phosphorylation events within cancer cells often become dysregulated, leading to oncogenic signaling and abnormal cell growth. phosphopeptides derived from aberrantly phosphorylated proteins that are presented on tumors and not on normal tissues by human leukocyte antigen (Hla) class I molecules are promising candidates for future cancer immunotherapies, because they are tumor specific and have been shown to elicit cytotoxic t cell responses. robust phosphopeptide enrichments that are suitable for low input amounts must be developed to characterize Hla-associated phosphopeptides from clinical samples that are limited by material availability. We present two complementary mass spectrometry-compatible, iron(III)-immobilized metal affinity chromatography (IMac) methods that use either nitrilotriacetic acid (nta) or iminodiacetic acid (IDa) in-house-fabricated columns. We developed these protocols to enrich for subfemtomole-level phosphopeptides from cell line and human tissue samples containing picograms of starting material, which is an order of magnitude less material than what is commonly used. In addition, we added a peptide esterification step to increase phosphopeptide specificity from these low-input samples. to date, hundreds of phosphopeptides displayed on melanoma, ovarian cancer, leukemia and colorectal cancer have been identified using these highly selective phosphopeptide enrichment protocols in combination with a program called 'caD neutral loss Finder' that identifies all spectra containing the characteristic neutral loss of phosphoric acid from phosphorylated serine and threonine residues. this methodology enables the identification of Hla-associated phosphopeptides presented by human tissue samples containing as little as nanograms of peptide material in 2 d.
IntroDuctIon
Our understanding of cancer progression has deepened over the past 60 years, resulting in the development of more effective treatment options. Immunotherapies, which harness the ability of the immune system to specifically eliminate unhealthy cells, have emerged as a promising new class of cancer therapeutics. Immunotherapeutics are designed to generate antitumor immune responses by stimulating adaptive immune cells [1] [2] [3] [4] [5] [6] [7] . During this response, antigen-presenting cells activate cytotoxic T cells by presenting cancer-specific antigens 1, 2, 5, 8, 9 . Activated T cells are then released to the periphery to survey cells throughout the body. Cytotoxic T cells determine cellular health by binding peptide antigens produced by the MHC class I pathway depicted in Figure 1 . Briefly, endogenous proteins are degraded by the proteasome and loaded onto HLA class I molecules. HLA-peptide complexes are then shuttled to the cell surface for display to circulating T cells. The majority of HLA-associated antigens are self-derived, and they do not elicit an immune response because T cells are rendered nonreactive to self-peptides before they are allowed to circulate in the periphery 9 . Tolerance toward self-antigens has a key role in preventing autoimmune responses, but it may also be the reason why many current immunotherapeutic candidates, which are derived from overexpressed or cancerassociated self-antigens, are not highly effective 6 .
Unique antigens, such as those resulting from dysregulated cellular signaling involved in cancer progression, are more attractive targets for cancer immunotherapeutics because they are distinct from healthy cells. Dysregulated cell signaling within tumors generates phosphorylated residues on proteins that are unique to the disease 1, 10, 11 . The proteolysis of these phosphorylated proteins and the presentation of tumor-specific phosphopeptides to the immune system by the HLA class I antigen-processing pathway distinguishes healthy cells from cancer cells 1, 10, 11 . We hypothesize that HLA class I-associated phosphopeptides are candidates for a cancer immunotherapy that harnesses the ability of the immune system to identify and specifically eliminate transformed cells 5 . We have identified HLA-associated phosphopeptides derived from dysregulated cell signaling pathways presented by cancer cells [1] [2] [3] [4] [5] and demonstrated that tumor-specific phosphopeptides elicit responses from healthy donor T cells 5 .
The analysis of HLA class I-associated phosphopeptides is based on an approach that has been used for several years [1] [2] [3] [4] . HLA class I molecules are immunopurified from cancer cells or tissues, and their associated peptides are eluted with acid. The combination of iron(III)-IMAC enrichment and high-performance liquid chromatography coupled to electrospray ionizationtandem mass spectrometry (HPLC-ESI-MS/MS) analysis is then used to identify tumor-specific phosphopeptide antigens that are assessed for immunological activity. Phosphopeptide enrichment is required because abundant unmodified peptides prevent the selection of phosphorylated peptides, which are present at the 1-5% level, for fragmentation during data-dependent HPLC-ESI-MS/MS analyses 2, 12, 13 . Therefore, iron(III)-IMAC is used to enrich for HLA-associated phosphopeptides before HPLC-ESI-MS/MS analysis 2,12,13 .
There are multiple published protocols that are compatible with mass spectrometry for phosphopeptide enrichment [14] [15] [16] [17] [18] [19] [20] [21] [22] , yet most of these methods were developed for high-throughput applications that require hundreds of micrograms (µg) to milligrams (mg) of protein material [14] [15] [16] [17] [18] [19] [22] [23] [24] [25] . Analysis of clinical samples may require phosphopeptide enrichment from nanograms (ng) to micrograms (µg) of peptide material, rendering high-throughput phosphopeptide enrichment protocols not applicable. The use of Ti(IV)-IMAC and metal affinity chromatography (MOAC) using TiO 2 for phosphopeptide enrichment is also well established 21, 26, 27 . Reports comparing phosphopeptide enrichment procedures have been published, but a consensus about which technique is best for each sample type has not been reached. For example, Zhou et al. 20, 28 have reported that TiO 2 and Ti 4+ enrichments have a higher affinity for phosphopeptides than Fe 3+ -based IMAC. Matheron et al. 27 have reported a comparative evaluation of Ti 4+ -IMAC and TiO 2 enrichment and demonstrated that minimal differences can be found when using either of these phosphopeptide enrichment techniques, but Fe-IMAC was not evaluated in this study. Conversely, Ruprecht et al. 22 have reported that phosphopeptides enriched by Fe-IMAC columns were 7 and 4 times higher in intensity than peptides enriched using Ti-IMAC tips and TiO 2 batches. In addition, many published phosphopeptide enrichment protocols do not incorporate the use of internal standards to monitor enrichment recovery or checkpoints to monitor peptide losses. Thus, we developed a phosphopeptide enrichment method for low-input samples that incorporates both checkpoints (Box 1) and internal standards to monitor peptide recovery. Although we present a low-throughput protocol, the throughput can be increased by chemically labeling samples using isobaric tags before phosphopeptide enrichment, such as iTRAQ (isobaric tags for relative and absolute quantification) or TMT (tandem mass tags), at the cost of absolute abundance estimation. We have previously demonstrated that HLA-associated phosphopeptides can be enriched by iron(III)-IMAC from micrograms of peptide material 2, 12, 13 . Despite our past successes, the phosphopeptide enrichment protocol required further optimization so that it could be applied to patient tumor samples. Two areas of improvement included reducing nonspecific binding and increasing peptide recoveries. Some improvement in nonspecific binding can be achieved by esterifying the sample; carboxylic acid residues on amino acid side chains and at the C terminus have an affinity for Fe 3+ cations, which can be reduced by a Fischer esterification. However, the most abundant nonspecific binding species observed in past studies were highly basic peptides and nitrogen-containing PEG polymer species, both of which negatively affected peptide separation and sequencing 2 . We believe 
Box 1 | Checkpoints
We recommend checking the sample at various stages of the PROCEDURE to monitor peptide recoveries. Below is a list of suggested checkpoints. Each analysis can be completed using Step 20 of the PROCEDURE. 1. Analyze 1% of the immunopurified HLA-associated peptide sample using HPLC-ESI-MS/MS to determine how much sample should be used for phosphopeptide enrichment. We recommend using samples isolated from 1 × 10 8 to 1 × 10 9 cell equivalents for desalting and enrichment. 2. Analyze 1% of the desalted sample to monitor peptide levels. We recommend adding phosphopeptide standards before desalting to detect peptide losses. 3. Analyze 1% of the esterified sample to ensure reaction completion. We recommend adding additional phosphopeptide standards before esterification to determine whether the esterification is complete and to detect peptide losses. 4. Collect and analyze the flow-through from different steps in the phosphopeptide enrichment to determine peptide losses. We recommend adding additional phosphopeptide standards before enrichment to monitor peptide losses. 22 have also recently demonstrated similar improvements to phosphopeptide enrichment using an on-column approach instead of the conventional batch-mode and StageTip protocols by enriching phosphopeptides from sample concentrations ranging from 100 µg to 1 mg. We also used an iron(III)-NTA-IMAC method similar to our IDA-IMAC method because of reports demonstrating that NTA resins provide enhanced phosphopeptide selectivity [16] [17] [18] [19] . Even with optimized phosphopeptide enrichment, phosphopeptide sequencing using HPLC-ESI-MS/MS is difficult because of the labile nature of the phosphorylation modification [21] [22] [23] . Collisionactivated dissociation (CAD) is one of the most commonly used fragmentation methods for HPLC-ESI-MS/MS experiments 5, 12, 13 . Higher-energy collisional dissociation (HCD) has also been applied in phosphoproteomic studies 29, 30 . Both CAD and HCD cause the loss of phosphoric acid upon fragmentation, resulting in tandem MS spectra (MS2) that can contain ambiguous sequencing and site localization information. On the other hand, the use of electron transfer dissociation (ETD) preserves labile phosphorylation modifications and produces high-quality phosphopeptide MS2 (refs. 31-35) . Although ETD appears to be a simple solution to the labile nature of phosphorylation sites, the mechanism of ETD is charge dependent, and it works best on peptides with a charge of +3 or greater 31, 35 . Heck and colleagues 36 have demonstrated that the use of electron transfer-HCD (ETHCD) enhances the detection rate of non-phosphopeptideenriched HLA-associated peptides that are highly charged (+3 or greater). However, most class I HLA-associated peptides are short peptides of 8-10 amino acid residues in length, with a predominant charge state of +2. These peptide characteristics are not ideal for sequencing using only ETD, and ETHCD acquisition can result in a slower duty cycle that can lead to undersampling. Therefore, we have found that it is beneficial to combine the two fragmentation methods, CAD and ETD, in order to obtain greater sequence information to confidently identify phosphopeptides and site-localize the modification (Supplementary Fig. 1 ).
In our research, both IDA-IMAC and NTA-IMAC enrichment protocols were applied to HLA-associated peptide mixtures isolated from cancer cell lines and human tumor tissue, resulting in the identification of hundreds of phosphopeptides presented to circulating T cells of the immune system 2, 5 . The two iron(III)-IMAC protocols are MS compatible, and they can be used to enrich for subfemtomole-level phosphopeptides from samples containing nanograms to micrograms of peptide material. The protocols described follow the general workflow outlined in our previous studies with modifications to reduce nonspecific binding and improve peptide recoveries from samples with low levels of peptide material. The described protocols enable the identification of cancer-associated HLA-associated phosphopeptides from submicrogram levels of peptide material, something not previously possible. Most important, these protocols could facilitate phosphoproteomic investigations of clinical samples, such as patient tumors and tumor microdissections, potentially directing personalized cancer immunotherapies. 2, 24 . Approximately 1 × 10 9 cells or 1 g of tissue can be lysed in 10 ml of buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% (vol/vol) CHAPS, 1 mM PMSF, aprotinin (5 µg/ml), leupeptin (10 µg/ml), pepstatin A (10 µg/ml), calyculin A (1 ug/ml) and phosphatase inhibitors II and III (Sigma). Homogenize tumor tissues using a mechanical homogenizer (TissueRuptor) after the addition of lysis buffer, and incubate for 2 h at 4 °C. Subject lysed cells and tissues to ultracentrifugation at 100,000g and 4 °C for 1 h, and incubate the resulting supernatant with NHS-sepharose beads preloaded with the pan-anti-HLA class I antibody W6/32. Elute peptides from purified class I HLA molecules with 10% (vol/vol) acetic acid and pass them through a 5-kDa-MWCO spin filter. Flash-freeze and lyophilize the peptide; it should be stable in this form at −80 °C for at least 6 months. ! cautIon If animal material is used, please note that appropriate institutional regulatory board guidelines must be followed; if human tissue is collected, please note that it is important to follow institutional guidelines regarding requesting permission for collection. 21 , and the LTQ-Orbitrap mass spectrometer (Thermo Fisher) custom-modified with front-end ETD 31, 34 . Thermo LTQ Orbitrap Velos mass spectrometers with back-end ETD and Thermo Orbitrap Fusion mass spectrometers 34 can also be used; we present data collected on specialized instrumentation because this was what we had available.
MaterIals

REAGENTS
HPLC-ESI-MS/MS solvents
HPLC-ESI-MS/MS equipment
The microcapillary HPLC column setup is described in detail by Marto and colleagues 37 . Acquire mass spectra (MS1) in the high-resolution Fourier transform or Orbitrap mass analyzer and MS2 in the linear ion trap of the instrument using CAD and front-end ETD 34 . Thermo LTQ Orbitrap Velos mass spectrometers with back-end ETD and Thermo Orbitrap Fusion mass spectrometers can be substituted for similar analyses. Acquire mass spectra using a method consisting of one highresolution MS1 scan (resolving power of 60,000 at m/z 400), followed by 12 data-dependent low-resolution MS2 scans acquired in the LTQ ion trap that include six CAD scans (3 m/z isolation window, 35% normalized collision energy) and six ETD MS2 scans (3 m/z isolation window, 45-ms reaction time with azulene radical anion) of the top six most abundant precursor ions. Instrument parameters include FTMS automatic gain control (AGC) target for MS1 scans of 2 × 10 5 (charges), ITMS n AGC target for MS2 scans of 1 × 10 4 (charges) and azulene ETD reagent target of 2 × 10 5 (charges). Datadependent instrument parameters should be set as follows: repeat count of 3, repeat duration of 10 and exclusion list duration of 10. Ions with a charge of +1 can be excluded if polymeric materials with +1 charge states are present in the sample and all scans are collected in centroid mode. However, some HLA-associated peptide ions reside in a +1 charge state, and excluding them from acquisition may result in a lower number of peptide identifications. 2| Pressure-load the peptide sample, using a pressure bomb apparatus similar to the one shown in supplementary Figure 2 , into a fused silica microcapillary cleanup column (360 µm o.d. × 150 µm i.d.) equipped with a 2-mm Kasil 1624 frit and packed with 5 cm of irregular C18 reversed-phase packing material (5-20 µm diameter and 120 Å pore size) at a flow rate of 0.5 µl/min.  crItIcal step We suggest using HLA-associated peptides isolated from 1 × 10 8 to 1 × 10 9 cell equivalents, and we suggest that the total volume of the sample be 50 µl. We also suggest using irregular C18 packing material for peptide desalting to prevent microcapillary columns from clogging.
3|
Wash the sample by pressure-loading 0.1 M acetic acid (half volume of sample) at a rate of 0.5 µl/min.
4|
Rinse the sample with 0.1 M acetic acid for 10 min at a back pressure of 12-15 bar using an HPLC column.  crItIcal step This wash removes salt from the sample, and it can be extended if needed. However, extremely hydrophilic peptides can be lost if the wash is extended for >20 min.
5|
Elute peptides from the cleanup column at the same back pressure into a microcentrifuge tube using a gradient of 0-80% solvent B over 40 min followed by a 30-min hold of 80% solvent B. The sample is collected with no fractionation during the elution.
6|
Dry the peptide-containing eluants in a Centrivap and store them at −35 °C.  pause poInt Store the desalted HLA-associated peptide sample at −35 °C for 1 week or −80 °C for up to 1 month. esterification • tIMInG 3 h 30 min  crItIcal Acidic residues (aspartic acid and glutamic acid) and the C terminus will be converted to methyl esters. Each conversion will result in an addition of 14 Da to the acidic residues and the C terminus. 7| Dry the HLA-associated peptides to completion after adding 50 µl of methanol using a CentriVap. Repeat the methanol addition and drying cycle three times to ensure that no water is present, because water will reverse esterification.  crItIcal step Use only anhydrous reagents for esterification, because water will reverse the reaction.
8|
Prepare esterification reagents by adding 160 µl of anhydrous acetyl chloride dropwise to 1 ml of anhydrous methanol (recommended for samples containing 50 pmol or less of total peptide). ! cautIon Add acetyl chloride dropwise because the reaction is exothermic. Wear appropriate safety equipment when you are handling acetyl chloride. phosphopeptide enrichment 13| Enrich for HLA-associated phosphopeptides using either the IDA-iron(III)-IMAC procedure or the NTA-iron(III)-IMAC procedure below. All steps should be completed at room temperature.  crItIcal step 50-60% overlap is observed between IDA-iron(III)-IMAC and NTA-iron(III)-IMAC enrichments, which is probably attributable to the data-dependent nature of the mass spectrometry acquisition. Either enrichment is suitable for sHLA-derived samples and cell line-derived samples. Higher selectivity is observed in NTA-iron(III) enrichments, making them a better choice for more complex tissue samples.  crItIcal step
Step 13A(v-viii) should be completed using flow rates <1 µl/min to prevent sample losses. We recommend 0.5 µl/min for these steps.  crItIcal step A flow rate faster than 1 µl/min will markedly reduce peptide recovery. If the flow rate is just under 1 µl/min, it is recommended that the flow-through of the IMAC column be reloaded onto the column to reduce peptide losses. We recommend using a flow rate of 0.5-1 µl/min. 15| Rinse the IMAC-precolumn combination with 0.01% (vol/vol) acetic acid for 10 min at a flow rate of 1 µl/min to ensure that no leaks are present.
16|
Elute the phosphopeptides directly onto the precolumn with a pressure load of 250 mM ascorbic acid in water (pH 2) at a flow rate between 0.5 and 1 µl/min for 35 min.  crItIcal step A flow rate faster than 1 µl/min will markedly reduce peptide recoveries.
17|
Rinse the IMAC-precolumn combination with 0.01% (vol/vol) acetic acid for 10 min at 1 µl/min. 18| Disconnect the precolumn from the IMAC column and rinse for 20 min with 0.1 M acetic acid at a flow rate of 60 nl/min on an HPLC column. ) fritted with a bottleneck containing irregular C18 packing material (5-20 µm diameter, 120 Å pore size) packed with 7 cm of C18 reverse-phase resin (5 µm diameter, 120 Å pore size) and equipped with a laser-pulled, 2-µm-diameter electrospray emitter tip.
19|
Dry the precolumn and connect it with a Teflon sleeve to a C18 microcapillary analytical column (360 µm o.d. × 50 µm i.d.
Hplc-esI-Ms/Ms analysis
• tIMInG 2 h 20| Gradient-elute the peptides using 0-60% solvent B in 60 min at a flow rate of 60 nl/min through a microelectrospray tip directly into a high-resolution mass spectrometer equipped with a reverse-phase HPLC microcapillary column. See Equipment Setup for more details about configuration and settings. Data analysis is discussed in ANTICIPATED RESULTS.  crItIcal step Longer gradients can be used to achieve a higher level of on-column separation, but this will result in wider peak widths. In addition, higher flow rates of 200-250 µl/min are suitable on uHPLC systems, such as the Proxeon Easy nLC1000. ? trouBlesHootInG Data analysis • tIMInG Variable: timing depends on the database search program used and the amount of manual validation required. the searches can take a few hours to >24 h (because of the large search space), and manual validation can take days. the neutral loss search takes minutes. 21| Perform data analysis by using the Xcalibur software (Thermo Electron Corporation). Search data files using OMSSA 41 (version 2.1.1) against the RefSeq database (downloaded June 2009). Searches of CAD and ETD spectra use the following parameters: no enzyme specificity, E value cutoff of 1, fixed modifications including methyl ester of aspartic acid, glutamic acid and C terminus, variable modifications including oxidation of methionine, phosphorylation of serine, threonine and tyrosine, and ±0.01 Da and ±0.35 Da for precursor and product ion masses, respectively. The data files can also be searched using an in-house program called CAD Neutral Loss Finder that identifies MS2 CAD spectra with the neutral loss of phosphoric acid (98 Da) characteristic of phosphopeptides. Use OMSSA and neutral loss search results to guide the analysis, and determine peptide sequences by accurate mass measurement and manual interpretation of the MS2. Any database search strategy using any Blast-formatted database that enables 'no enzyme' searches of both CAD and ETD data can be substituted for OMSSA to help guide manual interpretation.
22|
During manual validation, extract ion chromatograms for phosphopeptide database hits and precursor peptide ions that experience the loss of phosphoric acid during CAD fragmentation, and manually sequence CAD and ETD MS2 for all phosphopeptides. Often, the peptide ion fragments from both the CAD and ETD MS2 can be used together to determine phosphopeptide sequences. An example of manual validation is shown in supplementary Figure 3 . In the case of HLA-associated phosphopeptides, we chose to use manual validation because the population of phosphopeptides that results from unknown genetic mutations, splice variants and aberrant phosphorylations may not be present in human protein databases; therefore, they would not be found using traditional database search methods. This population of phosphopeptides is of high interest because they are likely to be cancer-specific peptides and novel candidates for immunotherapies.
? trouBlesHootInG Troubleshooting advice can be found in table 1. 
antIcIpateD results
We applied the IDA-iron(III)-IMAC and the NTA-iron(III)-IMAC protocols to two HLA-associated peptide samples to demonstrate the performance of each approach. Figure 2 shows a schematic describing workflows for HLA-associated phosphopeptide identification from an sHLA-transfected cell line (Fig. 2a) and tissue from a metastatic, human colorectal cancer tumor (Fig. 2b) . We present data on an immortalized ovarian cell line (FHIOSE) transfected with sHLA, because of the large amount of phosphopeptides present in this sample. We also present data on a colorectal patient tumor to demonstrate that the methods can be used on clinical samples. We suggest that HLA-associated peptides from noncancerous tissues and cell lines be analyzed as negative controls to determine which peptides are specific to cancerous cells. In addition, HLA-peptide isolations from well-characterized cell lines, such as the JY human lymphoblastoid cell line, can be used as positive controls [2] [3] [4] 36 . HLAs with their bound peptides were immunopurified from each sample, and their associated peptides were eluted with acid. The HLA-associated peptides were separated from denatured HLA using MWCO filters, and then they were desalted and esterified. HLA-associated phosphopeptides present at substoichiometric levels were enriched from the samples and analyzed by HPLC-ESI-MS/MS on an LTQ Orbitrap instrument. ) produced a larger number of correct phosphopeptide identifications when it was applied to the data collected from the NTA-iron(III)-IMAC enrichments. We estimate that ~70% of the phosphopeptides present in samples enriched using the NTA-iron(III)-IMAC protocol were found with protein database searches, compared with only 30-40% found when the IDA-iron(III)-IMAC protocol was searched. We made this estimation by comparing the phosphopeptides found with database searches against the RefSeq database to the phosphopeptides found by using our neutral loss search and manual validation. We believe that we observed more phosphopeptides in the database searches of Fe-NTA-IMAC experiments than in those of Fe-IDA-IMAC experiments because of the lower background observed in the NTA-iron(III)-IMAC enrichments. Therefore, MS2 from these experiments probably contained less noise and resulted in more database search matches. All CAD MS/MS spectra were also searched for the neutral loss of phosphoric acid (98 Da) characteristic of phosphopeptides using an in-house program written in Java called CAD Neutral Loss Finder, which is available at http://www.huntlab.org. A description of CAD Neutral Loss Finder can also be found in this website. All MS/MS phosphopeptide spectra were manually validated, and subsets were compared with synthetic peptides for further validation. The mass accuracy of all the identified peptides was observed to be <3 p.p.m.
Data evaluation and interpretation
Chromatograms depicting the separation of enriched phosphopeptides during HPLC-ESI-MS/MS analysis are shown in Figure 3a ,b. The average recovery of each type of enrichment is shown (Fig. 3a,b) . Average recoveries were calculated by comparing the peak areas of the extracted chromatograms representing the internal standard phosphopeptides spiked into the sample during checkpoints 2 (DRVyIHPF and RVKsPLFQF) and 3 (RTHsLLLLG) with the peak areas of two internal standard peptides (DRVYIHPFHL and HSDAVFTDNYTR), at 100 fmol each, added before HPLC-ESI-MS/MS analysis. Checkpoints are shown in Box 1. Average recoveries represent all peptide losses from Steps 1-20 of the phosphopeptide enrichment protocols. Our calculations represent relative abundances of phosphopeptides detected. We ran technical duplicates (enriching and analyzing the same sample in the mass spectrometer twice) for the FHIOSE phosphopeptide 
